Zacks
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
📉
AI Sentiment
Negative
3/10
- Home
- CRSP
as of 02-04-2026 3:51pm EST
$50.15
$1.85
-3.57%
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Upcoming Earnings Alert:
Get ready for potential market movements as CRISPR Therapeutics AG (CRSP) prepares to release earnings report on 11 Feb 2026.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 5.1B | IPO Year: | 2016 |
| Target Price: | $71.95 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.04 - $78.48 | Next Earning Date: | 02-11-2026 |
| Revenue: | $38,337,000 | Revenue Growth: | -81.10% |
| Revenue Growth (this year): | -79.21% | Revenue Growth (next year): | 1376.73% |
AI-Powered CRSP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.18%
69.18%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Jan 22, 2026
Avg Cost/Share
$60.23
Shares
60,000
Total Value
$3,613,800.00
Owned After
134,201
SEC Form 4
Prasad Raju
Sell
Chief Financial Officer
CRSP Jan 22, 2026
Avg Cost/Share
$60.19
Shares
34,972
Total Value
$2,104,964.68
Owned After
6,767
SEC Form 4
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Jan 20, 2026
Avg Cost/Share
$51.86
Shares
30,000
Total Value
$1,552,497.83
Owned After
134,201
Prasad Raju
Sell
Chief Financial Officer
CRSP Jan 6, 2026
Avg Cost/Share
$60.13
Shares
29,700
Total Value
$1,786,635.87
Owned After
6,767
Prasad Raju
Sell
Chief Financial Officer
CRSP Dec 22, 2025
Avg Cost/Share
$56.11
Shares
10,000
Total Value
$559,548.75
Owned After
6,767
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 22, 2026 | Sell | $60.23 | 60,000 | $3,613,800.00 | 134,201 | |
| Prasad Raju | CRSP | Chief Financial Officer | Jan 22, 2026 | Sell | $60.19 | 34,972 | $2,104,964.68 | 6,767 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 20, 2026 | Sell | $51.86 | 30,000 | $1,552,497.83 | 134,201 | |
| Prasad Raju | CRSP | Chief Financial Officer | Jan 6, 2026 | Sell | $60.13 | 29,700 | $1,786,635.87 | 6,767 | |
| Prasad Raju | CRSP | Chief Financial Officer | Dec 22, 2025 | Sell | $56.11 | 10,000 | $559,548.75 | 6,767 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
Zacks
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
📈
AI Sentiment
Highly Positive
8/10
Zacks
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
📉
AI Sentiment
Negative
3/10
Simply Wall St.
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap
📊
AI Sentiment
Positive
7/10
Compare CRSP vs Leading Stocks
See how CRSP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.